Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 1852517, 24 pages
https://doi.org/10.1155/2017/1852517
Review Article

Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma

1Division of Hematology, Department Patologia Umana dell’Adulto e dell’Età Evolutiva, University of Messina, Località Gazzi, Via Consolare Valeria, Messina, Italy
2Institute of Applied Sciences and Intelligent Systems “Eduardo Caianiello” (ISASI)-National Research Council of Italy (CNR), Messina Unit, Via Torre Bianca, Messina, Italy
3School and Division of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital “G. Martino”, Località Gazzi, Via Consolare Valeria, Messina, Italy

Correspondence should be addressed to Alessandro Allegra; ti.eminu@argellaa

Received 24 May 2017; Accepted 11 September 2017; Published 26 September 2017

Academic Editor: Mirella Giovarelli

Copyright © 2017 Caterina Musolino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Kyle and S. V. Rajkumar, “Multiple myeloma,” The New England Journal of Medicine, vol. 351, pp. 1860–1873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. L. M. Coussen and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Cao, T. Luetkens, S. Kobold et al., “The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients,” Experimental Hematology, vol. 38, pp. 860–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hallek, P. L. Bergsagel, and K. C. Anderson, “Multiple myeloma: increasing evidence for a multistep transformation process,” Blood, vol. 91, pp. 3–21, 1998. View at Google Scholar
  5. I. Van Riet, “Homing mechanisms of myeloma cells,” Pathologie-biologie, vol. 47, pp. 98–108, 1999. View at Google Scholar
  6. M. Kawano, T. Hirano, T. Matsuda et al., “Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas,” Nature, vol. 332, pp. 83–85, 1988. View at Publisher · View at Google Scholar
  7. A. Zlotnik, “Chemokines and cancer,” International Journal of Cancer, vol. 119, pp. 2026–2029, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Zdzisinska, A. Bojarska-Junak, A. Dmoszynska, and C. Kandefer-Szerszen, “Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells,” Archivum Immunologiae et Therapiae Experimentalis (Warsz), vol. 56, pp. 207–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Raman, P. J. Baugher, Y. M. Thu, and A. Richmond, “Role of chemokines in tumor growth,” Cancer Letters, vol. 256, pp. 137–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. W. Lee, H. Y. Chung, L. A. Ehrlich et al., “IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells,” Blood, vol. 103, pp. 2308–2315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Pellegrino, R. Ria, G. Di Pietro et al., “Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells,” British Journal of Haematology, vol. 129, pp. 248–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Podar, Y. T. Tai, F. E. Davies et al., “Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration,” Blood, vol. 98, pp. 428–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Podar, Y. T. Tai, B. K. Lin et al., “Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation,” The Journal of Biological Chemistry, vol. 277, pp. 7875–7881, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Vacca, D. Ribatti, A. M. Roccaro, R. Ria, L. Palermo, and F. Dammacco, “Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma,” Acta Haematologica, vol. 106, pp. 162–169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Niida, M. Kaku, H. Amano et al., “Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption,” The Journal of Experimental Medicine, vol. 190, pp. 293–298, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Tanaka, M. Abe, M. Hiasa et al., “Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin,” Clinical Cancer Research, vol. 13, pp. 816–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. Dewald, F. Colomb, M. Bobowski-Gerard, S. Groux-Degroote, and P. Delannoy, “Role of cytokine-induced glycosylation changes in regulating cell interactions and cell signaling in inflammatory diseases and cancer,” Cell, vol. 5, no. 43, 2016. View at Publisher · View at Google Scholar
  18. L. Sedlarikova, K. Sadílková, L. Kubiczková, R. Hájek, and S. Sevčíková, “Cytokine profiles of multiple myeloma and Waldenstrom macroglobulinemia,” Klinická Onkologie, vol. 27, no. 1, pp. 18–23, 2014. View at Publisher · View at Google Scholar
  19. O. Mehtap, E. B. Atesoglu, P. Tarkun, A. Hacihanefioglu, I. Dolasik, and M. M. Musul, “IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis,” Journal of Postgraduate Medicine, vol. 60, no. 2, pp. 141–144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. K. Abbas, K. M. Murphy, and A. Sher, “Functional diversity of helper T lymphocytes,” Nature, vol. 383, pp. 787–793, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. T. R. Mosmann and S. Sad, “The expanding universe of T-cell subsets: Th1, Th2 and more,” Immunology Today, vol. 17, no. 3, pp. 138–146, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Park, Z. Li, X. O. Yang et al., “A distinct lineage of CD4 T cells regulated tissue inflammation by producing interleukin 17,” Nature Immunology, vol. 6, no. 11, pp. 1133–1141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Bettelli, M. Oukka, and V. K. Kuchroo, “T(H)-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Sakaguchi, M. Ono, R. Setoguchi et al., “Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease,” Immunology Reviews, vol. 212, pp. 8–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Ryba-Stanislawowska, M. Skrzypkowska, M. Myśliwiec, and J. Myśliwska, “Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+) IL17A(+) Th17 cells in patients with type 1 diabetes,” Human Immunology, vol. 74, no. 6, pp. 701–707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. C. Boissier, E. Assier, G. Falgarone, and N. Bessis, “Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm,” Joint, Bone, Spine, vol. 75, no. 4, pp. 373–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Cheng, X. Yu, Y. J. Ding et al., “The Th17/Treg imbalance in patients with acute coronary syndrome,” Clinical Immunology, vol. 127, no. 1, pp. 89–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Zhang, L. X. Song, X. Zhang, C. Xiao, and C. K. Chang, “Function of peripheral blood Th17 cells in patients with multiple myeloma,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 21, no. 5, pp. 1187–1189, 2013. View at Google Scholar
  29. P. Feng, R. Yan, X. Dai, X. Xie, H. Wen, and S. Yang, “The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma,” Inflammation, vol. 38, no. 2, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Wang, P. Chen, Y. Jia et al., “Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma,” Oncotarget, vol. 6, no. 20, pp. 17958–17967, 2015. View at Publisher · View at Google Scholar
  31. T. Atanackovic, Y. Cao, T. Luetkens et al., “CD4+CD25+ FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation,” Haematologica, vol. 3, pp. 423–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. H. Prabhala, P. Neri, J. Bae et al., “Dysfunctional T regulatory cells in multiple myeloma,” Blood, vol. 1, pp. 301–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Huang, Y. Luo, Y. Liang et al., “CD4+CD25+ cells in multiple myeloma related renal impairment,” Scientific Reports, vol. 5, article 16565, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Gabay, C. Lamacchia, and G. Palmer, “IL-1 pathways in inflammation and human diseases,” Nature Reviews Rheumatology, vol. 6, pp. 232–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Akdis, S. Burgler, R. Crameri et al., “Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases,” The Journal of Allergy and Clinical Immunology, vol. 127, pp. 701–721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Xiong, K. A. Donovan, M. P. Kline et al., “Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1,” Journal of Interferon & Cytokine Research, vol. 26, pp. 83–95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Lust, M. Q. Lacy, S. R. Zeldenrust et al., “Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component,” Mayo Clinic Proceedings, vol. 84, pp. 114–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Lust, M. Q. Lacy, S. R. Zeldenrust et al., “Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma,” American Journal of Hematology, vol. 91, pp. 571–574, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. A. X. H. Goh, S. Bertin-Maghit, S. P. Yeo et al., “A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy,” MAbs, vol. 6, no. 3, pp. 765–773, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. M. de la Rosa, S. Rutz, H. Dorninger, and A. Scheffold, “Interleukin‐2 is essential for CD4+ CD25+ regulatory T cell function,” European Journal of Immunology, vol. 34, pp. 2480–2488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. D. M. Benson Jr, C. E. Bakan, A. Mishra et al., “The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody,” Blood, vol. 116, pp. 2286–2294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Zeiser, H. Bertz, A. Spyridonidis, L. Houet, and J. Finke, “Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives,” Bone Marrow Transplantation, vol. 34, pp. 923–928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Szmania, B. Balasa, P. Malaviarachi et al., “CS1 is expressed on myeloma cells from early stage, late stage, and drug-treated multiple myeloma patients, and is selectively targeted by the huluc63 antibody,” Blood, vol. 108, p. 660a, 2006. View at Google Scholar
  44. J. Shi, G. Tricot, S. Szmania et al., “Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation,” British Journal of Haematology, vol. 143, pp. 641–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Sarkar, W. T. V. Germeraad, K. M. A. Rouschop et al., “Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells,” PLoS One, vol. 8, no. 5, article e64835, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Wolf, S. Rose-John, and C. Garbers, “Interleukin-6 and its receptors: a highly regulated and dynamic system,” Cytokine, vol. 70, pp. 11–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Hirano, “Revisiting the 1986 molecular cloning of interleukin 6,” Frontiers in Immunology, vol. 5, p. 456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil, “Expression of functional interleukin 15 receptor and autocrine production of interleukin 15 as mechanism of tumor propagation in multiple myeloma,” Blood, vol. 95, pp. 610–618, 2000. View at Google Scholar
  49. M. G. Alexandrakis, F. H. Passam, A. Boula et al., “Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma,” Annals of Hematology, vol. 82, pp. 19–23, 2003. View at Publisher · View at Google Scholar
  50. G. Tsirakis, C. A. Pappa, M. Kaparou et al., “The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma,” Tumor Biology, vol. 34, pp. 859–864, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. T. T. Pelliniemi, K. Irjala, K. Mattila et al., “Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group,” Blood, vol. 85, pp. 765–771, 1995. View at Google Scholar
  52. S. Joshi, N. Gupta, R. Khan et al., “Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma,” Clinical & Translational Oncology, vol. 18, no. 2, pp. 132–137, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Matthes, B. Manfroi, and B. Huard, “Revisiting IL-6 antagonism in multiple myeloma,” Critical Reviews in Oncology/Hematology, vol. 105, pp. 1–4, 2016. View at Publisher · View at Google Scholar
  54. A. Markham and T. Patel, “Siltuximab: first global approval,” Drugs, vol. 74, no. 10, pp. 1147–1152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Bagcchi, “Siltuximab in transplant-ineligible patients with myeloma,” The Lancet Oncology, vol. 15, no. 8, article e309, 2014. View at Publisher · View at Google Scholar
  56. S. K. Thomas, A. Suvorov, L. Noens et al., “Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma,” Cancer Chemotherapy and Pharmacology, vol. 1, pp. 35–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Kanoh and B. K. Rubin, “Mechanisms of action and clinical application of macrolides as immunomodulatory medications,” Clinical Microbiology Reviews, vol. 23, no. 3, pp. 590–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Nakamura, Y. Kikukawa, M. Takeya, H. Mitsuya, and H. Hata, “Clarithromycin attenuates autophagy in myeloma cells,” International Journal of Oncology, vol. 37, pp. 815–820, 2010. View at Publisher · View at Google Scholar
  59. S. Moriya, X. F. Che, S. Komatsu et al., “Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells,” International Journal of Oncology, vol. 42, no. 5, pp. 1541–1550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. B. G. M. Durie, “Clarithromycin (Biaxin) as primary treatment for myeloma,” Blood, vol. 90, no. 279a, abstract supplement 1, 1997. View at Google Scholar
  61. P. Musto, A. Falcone, G. Sanpaolo, C. Bodenizza, M. Carotenuto, and A. M. Carella, “Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report,” Haematologica, vol. 87, no. 6, pp. 658-659, 2002. View at Google Scholar
  62. T. C. Morris, L. Ranaghan, and J. Morrison, “Phase II trial of clarithromycin and pamidronate therapy in myeloma,” Medical Oncology (Northwood, London, England), vol. 18, no. 1, pp. 79–84, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. A. K. Stewart, S. Trudel, B. M. Al-Berouti, D. M. Sutton, and J. Meharchand, “Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma,” Blood, vol. 93, no. 12, p. 4441, 1999. View at Google Scholar
  64. P. Moreau, A. Huynh, T. Facon et al., “Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM),” Leukemia, vol. 13, no. 3, pp. 490-491, 1999. View at Publisher · View at Google Scholar
  65. R. Burger, “Impact of interleukin-6 in hematological malignancies,” Transfusion Medicine and Hemotherapy, vol. 40, no. 5, pp. 336–343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Sakamoto, K. Mikasa, T. Majima et al., “Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer,” Chemotherapy, vol. 47, pp. 444–451, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. I. B. McInnes, A. Kavanaugh, A. B. Gottlieb et al., “Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial,” Lancet, vol. 382, pp. 780–789, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. M. J. Brunda, L. Luistro, R. R. Warrier et al., “Antitumor and antimetastatic activity of interleukin 12 against murine tumors,” The Journal of Experimental Medicine, vol. 178, pp. 1223–1230, 1993. View at Publisher · View at Google Scholar
  69. M. P. Colombo and G. Trinchieri, “Interleukin-12 in anti-tumor immunity and immunotherapy,” Cytokine & Growth Factor Reviews, vol. 13, pp. 155–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. M. J. Smyth, M. Taniguchi, and S. E. Street, “The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent,” Journal of Immunology, vol. 165, pp. 2665–2670, 2000. View at Publisher · View at Google Scholar
  71. I. Airoldi, E. Di Carlo, C. Cocco et al., “Endogenous IL-12 triggers an antiangiogenic program in melanoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 3996–4001, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Dias, R. Boyd, and F. Balkwill, “IL-12 regulates VEGF and MMPs in a murine breast cancer model,” International Journal of Cancer, vol. 78, pp. 361–365, 1998. View at Publisher · View at Google Scholar
  73. D. G. Duda, M. Sunamura, L. Lozonschi et al., “Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12,” Cancer Research, vol. 60, pp. 1111–1116, 2000. View at Google Scholar
  74. C. Sgadari, A. L. Angiolillo, and G. Tosato, “Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10,” Blood, vol. 87, pp. 3877–3882, 1996. View at Google Scholar
  75. E. E. Voest, B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman, “Inhibition of angiogenesis in vivo by interleukin 12,” Journal of the National Cancer Institute, vol. 87, pp. 581–586, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. I. Airoldi, E. Di Carlo, B. Banelli et al., “The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies,” The Journal of Clinical Investigation, vol. 113, pp. 1651–1659, 2004. View at Publisher · View at Google Scholar
  77. I. Airoldi, C. Cocco, E. Di Carlo et al., “Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells,” Cancer Research, vol. 66, pp. 3978–3980, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Airoldi, E. Di Carlo, C. Cocco et al., “Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy,” Blood, vol. 106, pp. 3846–3853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. B. T. Lin and L. M. Weiss, “Primary plasmacytoma of lymph nodes,” Human Pathology, vol. 28, pp. 1083–1090, 1997. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Airoldi, C. Cocco, N. Giuliani et al., “Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target,” Blood, vol. 112, no. 3, pp. 750–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Wang, X. Feng, J. Wang et al., “Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells,” Anti-Cancer Drugs, vol. 25, no. 3, pp. 282–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Q. Lacy, S. Jacobus, E. A. Blood, N. E. Kay, S. V. Rajkumar, and P. R. Greipp, “Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group,” Leukemia Research, vol. 33, no. 11, pp. 1485–1489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Hansson, A. O. Abdalla, A. Moshfegh et al., “Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients,” Clinical Cancer Research, vol. 13, no. 5, pp. 1503–1510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. T. A. Fehniger and M. A. Caligiuri, “Interleukin 15: biology and relevance to human disease,” Blood, vol. 97, pp. 14–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. T. A. Waldmann, “The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design,” Nature Reviews. Immunology, vol. 6, pp. 595–601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Sanjabi, M. M. Mosaheb, and R. A. Flavell, “Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells,” Immunity, vol. 31, pp. 131–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. A. Stoklasek, K. S. Schluns, and L. Lefrancois, “Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo,” Journal of Immunology, vol. 177, pp. 6072–6080, 2006. View at Publisher · View at Google Scholar
  88. S. Dubois, H. J. Patel, M. Zhang, T. A. Waldmann, and J. R. Muller, “Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action,” Journal of Immunology, vol. 180, pp. 2099–2106, 2008. View at Publisher · View at Google Scholar
  89. M. Epardaud, K. G. Elpek, M. P. Rubinstein et al., “Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells,” Cancer Research, vol. 68, pp. 2972–2983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Pappa, S. Miyakis, G. Tsirakis et al., “Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma,” Cytokine, vol. 37, pp. 171–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. W. Xu, M. Jones, B. Liu et al., “Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma,” Cancer Research, vol. 73, no. 10, pp. 3075–3086, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. D. M. Center, H. Kornfeld, and W. W. Cruikshank, “Interleukin 16 and its function as a CD4 ligand,” Immunology Today, vol. 17, pp. 476–481, 1996. View at Publisher · View at Google Scholar · View at Scopus
  93. V. M. Lauta, “A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications,” Cancer, vol. 97, pp. 2440–2452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. T. H. Rand, W. W. Cruikshank, D. M. Center, and P. F. Weller, “CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration,” The Journal of Experimental Medicine, vol. 173, pp. 1521–1528, 1991. View at Publisher · View at Google Scholar
  95. M. G. Alexandrakis, F. H. Passam, D. S. Kyriakou et al., “Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity,” American Journal of Hematology, vol. 75, pp. 101–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. S. F. Long, G. A. Chen, and M. S. Fang, “Levels of interleukin-16 in peripheral blood of 52 patients with multiple myeloma and its clinical significance,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 12, pp. 22520–22524, 2015. View at Google Scholar
  97. D. Atanackovic, Y. Hildebrandt, J. Templin et al., “Role of interleukin 16 in multiple myeloma,” Journal of the National Cancer Institute, vol. 104, no. 13, pp. 1005–1020, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Kuwabara, F. Ishikawa, M. Kondo, and T. Kakiuchi, “The role of IL-17 and related cytokines in inflammatory autoimmune diseases,” Mediators of Inflammation, vol. 2017, Article ID 3908061, 11 pages, 2017. View at Publisher · View at Google Scholar
  99. C. Y. Du, R. Y. Yang, C. Li, and L. J. Duan, “Correlation of Th17 cells and IL-17 level in multiple myeloma patients with pathogenesis of multiple myeloma,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 25, no. 1, pp. 147–150, 2017. View at Google Scholar
  100. S. Campo, A. Allegra, A. D'Ascola et al., “MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma,” British Journal of Haematology, vol. 165, no. 6, pp. 801–813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Li, B. Zhang, W. Li et al., “MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma,” Leukemia Research, vol. 49, pp. 73–79, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. J. A. Gracie, S. E. Robertson, and I. B. McInnes, “Interleukin-18,” Journal of Leukocyte Biology, vol. 73, pp. 213–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. K. Nakanishi, T. Yoshimoto, H. Tsutsui, and H. Okamura, “Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu,” Cytokine & Growth Factor Reviews, vol. 12, pp. 53–72, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. Li, N. Li, Z. Yan et al., “Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma,” Hematology, vol. 21, no. 3, pp. 144–151, 2016. View at Publisher · View at Google Scholar · View at Scopus
  105. M. G. Alexandrakis, F. H. Passam, K. Sfiridaki et al., “Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival,” Leukemia Research, vol. 28, pp. 259–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. M. A. Amin, B. J. Rabquer, P. J. Mansfield et al., “Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases,” Annals of the Rheumatic Diseases, vol. 69, pp. 2204–2212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. C. A. Pappa, M. G. Alexandrakis, A. Boula et al., “Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients,” Hematological Oncology, vol. 31, no. 4, pp. 201–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Trifari, C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits, “Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells,” Nature Immunology, vol. 10, pp. 864–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Cella, A. Fuchs, W. Vermi et al., “A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity,” Nature, vol. 457, pp. 722–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. M. de Oliveira Neto, J. R. Ferreira Jr, D. Colau et al., “Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains,” Biophysical Journal, vol. 94, pp. 1754–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Bleicher, P. R. de Moura, L. Watanabe et al., “Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism,” FEBS Letters, vol. 582, pp. 2985–2992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Boniface, F. X. Bernard, M. Garcia, A. L. Gurney, J. C. Lecron, and F. Morel, “IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes,” Journal of Immunology, vol. 174, pp. 3695–3702, 2005. View at Publisher · View at Google Scholar
  113. H. Ikeuchi, T. Kuroiwa, N. Hiramatsu et al., “Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine,” Arthritis and Rheumatism, vol. 52, pp. 1037–1046, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat, “IL-22 increases the innate immunity of tissues,” Immunity, vol. 21, pp. 241–254, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. H. Takatori, Y. Kanno, W. T. Watford et al., “Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22,” The Journal of Experimental Medicine, vol. 206, pp. 35–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Wolk, E. Witte, K. Witte, K. Warszawska, and R. Sabat, “Biology of interleukin-22,” Seminars in Immunopathology, vol. 32, p. 1731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Eyerich, K. Eyerich, D. Pennino et al., “Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling,” The Journal of Clinical Investigation, vol. 119, pp. 3573–3585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. K. E. Nograles, L. C. Zaba, A. Shemer et al., “IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells,” The Journal of Allergy and Clinical Immunology, vol. 123, pp. 1244–1252.e2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. Z. J. Ye, Q. Zhou, W. Yin et al., “Interleukin 22-producing CD4+ T cells in malignant pleural effusion,” Cancer Letters, vol. 326, pp. 23–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. X. Xu, Y. Tang, S. Guo et al., “Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression,” Pancreas, vol. 43, pp. 470–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. I. Kryczek, Y. Lin, N. Nagarsheth et al., “IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L,” Immunity, vol. 40, pp. 772–784, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. C. Musolino, A. Allegra, M. Ferraro et al., “Involvement of T2677T multidrug resistance gene polymorphism in interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients,” Acta Oncologica, vol. 51, no. 3, pp. 406–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Gangemi, A. Allegra, A. Alonci et al., “Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia,” Blood Cells, Molecules & Diseases, vol. 50, no. 1, pp. 39-40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. G. Di Lullo, M. Marcatti, S. Heltai et al., “Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival,” Oncoimmunology, vol. 4, no. 5, article e1005460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. G. Tsirakis, C. A. Pappa, A. Kolovou, M. Kokonozaki, I. Neonakis, and M. G. Alexandrakis, “Clinical significance of interleukin-22 in multiple myeloma,” Hematology, vol. 3, p. 143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. E. Duvallet, L. Semerano, E. Assier, G. Falgarone, and M. C. Boissier, “Interleukin-23: a key cytokine in inflammatory diseases,” Annals of Medicine, vol. 43, pp. 503–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. C. Parham, M. Chirica, J. Timans et al., “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R,” Journal of Immunology, vol. 168, pp. 5699–5708, 2002. View at Publisher · View at Google Scholar
  128. R. J. Carmody, Q. Ruan, H. C. Liou, and Y. H. Chen, “Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells,” Journal of Immunology, vol. 178, pp. 186–191, 2007. View at Publisher · View at Google Scholar
  129. F. A. Verreck, T. de Boer, D. M. Langenberg et al., “Human IL-23-producing type 1 macrophages pro-mote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, pp. 4560–4565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. J. L. Langowski, R. A. Kastelein, and M. Oft, “Swords into plowshares: IL-23 repurposes tumor immune surveillance,” Trends in Immunology, vol. 28, pp. 207–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. J. L. Langowski, X. Zhang, L. Wu et al., “IL-23 promotes tumour incidence and growth,” Nature, vol. 442, pp. 461–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Tartour, F. Fossiez, I. Joyeux et al., “Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice,” Cancer Research, vol. 59, pp. 3698–3704, 1999. View at Google Scholar
  133. S. Oniki, H. Nagai, T. Horikawa et al., “Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma,” Cancer Research, vol. 66, pp. 6395–6404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Ugai, O. Shimozato, L. Yu et al., “Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects,” Cancer Gene Therapy, vol. 10, pp. 771–778, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. X. Yuan, J. Hu, M. L. Belladonna, K. L. Black, and J. S. Yu, “Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit anti-tumor activity against intracranial glioma,” Cancer Research, vol. 66, pp. 2630–2638, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Kaiga, M. Sato, H. Kaneda, Y. Iwakura, T. Takayama, and H. Tahara, “Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12,” Journal of Immunology, vol. 178, pp. 7571–7580, 2007. View at Publisher · View at Google Scholar
  137. W. W. Overwijk, K. E. de Visser, F. H. Tirion et al., “Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant,” Journal of Immunology, vol. 176, pp. 5213–5222, 2006. View at Publisher · View at Google Scholar
  138. M. G. Alexandrakis, C. A. Pappa, S. Miyakis et al., “Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma,” European Journal of Internal Medicine, vol. 17, pp. 412–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. J. M. Quinn, N. A. Sims, H. Saleh et al., “IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice,” Journal of Immunology, vol. 181, pp. 5720–5729, 2008. View at Publisher · View at Google Scholar
  140. S. Kamiya, C. Nakamura, T. Fukawa et al., “Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation,” Journal of Bone and Mineral Metabolism, vol. 25, pp. 277–285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. K. Noonan, L. Marchionni, J. Anderson, D. Pardoll, G. D. Roodman, and I. Borrello, “A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma,” Blood, vol. 116, pp. 3554–3563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. G. Trinchieri, S. Pflanz, and R. A. Kastelein, “The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses,” Immunity, vol. 19, pp. 641–644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Pflanz, L. Hibbert, J. Mattson et al., “WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27,” Journal of Immunology, vol. 172, pp. 2225–2231, 2004. View at Publisher · View at Google Scholar
  144. M. Xu, I. Mizoguchi, N. Morishima, Y. Chiba, J. Mizuguchi, and T. Yoshimoto, “Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27,” Clinical & Developmental Immunology, vol. 2010, article 832454, 9 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. C. Cocco, F. Morandi, and I. Airoldi, “Interleukin-27 and interleukin-23 modulate human plasmacell functions,” Journal of Leukocyte Biology, vol. 89, pp. 729–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. F. Larousserie, P. Charlot, E. Bardel, J. Froger, R. A. Kastelein, and O. Devergne, “Differential effects of IL-27 on human B cell subsets,” Journal of Immunology, vol. 176, pp. 5890–5897, 2006. View at Publisher · View at Google Scholar
  147. M. Hisada, S. Kamiya, K. Fujita et al., “Potent antitumor activity of interleukin-27,” Cancer Research, vol. 64, pp. 1152–1156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Vacca and D. Ribatti, “Bone marrow angiogenesis in multiple myeloma,” Leukemia, vol. 20, pp. 193–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  149. N. Giuliani, S. Colla, M. Lazzaretti et al., “Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis,” Blood, vol. 102, pp. 638–645, 2003. View at Publisher · View at Google Scholar · View at Scopus
  150. S. Uneda, F. Matsuno, T. Sonoki, I. Tniguchi, F. Kawano, and H. Hata, “Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells,” Haematologica, vol. 88, pp. 113–115, 2003. View at Google Scholar
  151. L. Vincent, D. K. Jin, M. A. Karajannis et al., “Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells,” Cancer Research, vol. 65, pp. 3185–3192, 2005. View at Publisher · View at Google Scholar
  152. J. R. Bradley, “TNF-mediated inflammatory disease,” The Journal of Pathology, vol. 214, pp. 149–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. G. Olmos and J. Lladó, “Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity,” Mediators of Inflammation, vol. 2014, Article ID 861231, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Hoffmann and D. Baltimore, “Circuitry of nuclear factor kappaB signaling,” Immunological Reviews, vol. 210, pp. 171–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. Y. Dai, X. Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant, “Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells,” Blood, vol. 103, pp. 2761–2770, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. J. J. Keats, R. Fonseca, M. Chesi et al., “Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma,” Cancer Cell, vol. 12, pp. 131–144, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. P. Roy, T. Mukherjee, B. Chatterjee, B. Vijayaragavan, B. Banoth, and S. Basak, “Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway,” Oncogene, pp. 1–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Neben, J. Mytilineos, T. M. Moehler et al., “Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma,” Blood, vol. 100, pp. 2263–2265, 2002. View at Google Scholar
  160. K. Kadar, M. Kovacs, I. Karadi et al., “Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma,” Leukemia Research, vol. 32, pp. 1499–1504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. E. V. Iokupova, O. V. Grinchuk, D. K. Kalimullina et al., “Molecular genetic analysis of the IL-6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma,” Molekuliarnaia Biologiia (Mosk), vol. 37, pp. 420–424, 2003. View at Google Scholar
  162. C. Basmacı, M. Pehlivan, A. G. Tomatır et al., “Effects of TNFalpha, NOS3, MDR1 gene polymorphisms on clinical parameters, prognosis and survival of multiple myeloma cases,” Asian Pacific Journal of Cancer Prevention, vol. 17, no. 3, pp. 1009–1014, 2016. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Du, Z. C. Yuan, C. Y. Zhang et al., “Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma,” Zhonghau Xue Ye Xeu Za Zhi, vol. 30, pp. 649–653, 2009. View at Google Scholar
  164. L. E. Perez, N. Parque, K. Shain et al., “Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP,” Journal of Immunology, vol. 180, pp. 1545–1555, 2008. View at Publisher · View at Google Scholar
  165. H. Rauert, T. Stuhmer, R. Bargou, H. Wajant, and D. Siegmund, “TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms,” Cell Death & Disease, vol. 2, article e194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. Y. Kawano, M. Moschetta, S. Manier et al., “Targeting the bone marrow microenvironment in multiple myeloma,” Immunological Reviews, vol. 263, pp. 160–172, 2015. View at Publisher · View at Google Scholar · View at Scopus
  167. V. Jurisic and M. Colovic, “Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma,” Medical Oncology, vol. 19, pp. 133–139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  168. M. Jourdan, K. Tarte, E. Legouffe, J. Brochier, J. F. Rossi, and B. Klein, “Tumor necrosis factor is a survival and proliferation factor for human myeloma cells,” European Cytokine Network, vol. 10, pp. 65–70, 1999. View at Google Scholar
  169. X. S. Wang, Q. Shi, L. A. Williams et al., “Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma,” Leukemia & Lymphoma, vol. 56, pp. 1335–1341, 2015. View at Publisher · View at Google Scholar · View at Scopus
  170. T. Latif, N. Chauhan, R. Khan, A. Moran, and S. Z. Usmani, “Thalidomide and its analogues in the treatment of multiple myeloma,” Experimental Hematology & Oncology, vol. 1, p. 27, 2012. View at Publisher · View at Google Scholar
  171. C. Geng, J. Hou, Y. Zhao et al., “A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma,” American Journal of Hematology, vol. 89, pp. 1037–1042, 2014. View at Publisher · View at Google Scholar · View at Scopus
  172. G. W. Muller, R. Chen, S. Y. Huang et al., “Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production,” Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1625–1630, 1999. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Maıga, P. Gomez-Bougie, S. Bonnaud et al., “Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma,” British Journal of Cancer, vol. 108, pp. 1801–1806, 2013. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Allegra, G. Penna, A. Alonci et al., “Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma,” European Journal of Haematology, vol. 90, no. 6, pp. 441–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. S. M. Collins, C. E. Bakan, G. D. Swartzel et al., “Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC,” Cancer Immunology, Immunotherapy, vol. 62, pp. 1841–1849, 2013. View at Publisher · View at Google Scholar · View at Scopus
  176. B. Balasa, R. Yun, N. A. Belmar et al., “Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF alpha pathways,” Cancer Immunology, Immunotherapy, vol. 64, pp. 61–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  177. H. W. Lee, S. J. Park, B. K. Choi, H. H. Kim, K. O. Nam, and B. S. Kwon, “4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL, and Bfl-1,” Journal of Immunology, vol. 169, pp. 4882–4288, 2002. View at Publisher · View at Google Scholar
  178. C. Chester, S. Ambulkar, and H. E. Kohrt, “4-1BB agonism: adding the accelerator to cancer immunotherapy,” Cancer Immunology, Immunotherapy, vol. 65, pp. 1243–1248, 2016. View at Publisher · View at Google Scholar · View at Scopus
  179. A. Morales-Kastresana, E. Cataln, S. Hervas-Stubbs et al., “Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb,” Journal for Immunotherapy of Cancer, vol. 1, p. 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  180. N. H. Segal, A. K. Gopal, S. Bhatia et al., “A phase 1 study of PF-0582566 (anti-4-1BB) in patients with advanced cancer,” Journal of Clinical Oncology, vol. 32, supplement: abstract 3007, p. 5, 2014. View at Google Scholar
  181. J. Moreaux, E. Legouffe, E. Jourdan et al., “BAFF and APRIL protect myeloma cells from apoptosis induced interleukin 6 deprivation and dexamethasone,” Blood, vol. 103, pp. 3148–3157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  182. M. G. Alexandrakis, P. Roussou, C. A. Pappa et al., “Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma,” BioMed Research International, vol. 2013, Article ID 389579, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. M. Fragioudaki, A. Boula, G. Tsirakis et al., “B cell-activating factor: its clinical significance in multiple myeloma patients,” Annals of Hematology, vol. 91, pp. 1413–1418, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. M. Fragioudaki, G. Tsirakis, C. A. Pappa et al., “Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma,” Leukemia Research, vol. 36, pp. 1004–1008, 2012. View at Publisher · View at Google Scholar · View at Scopus
  185. D. Lemancewicz, L. Bolkum, E. Jablonska et al., “Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features,” Leukemia Research, vol. 37, pp. 1089–1093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  186. J. Hengeveld and J. Kersten, “B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?” Blood Cancer Journal, vol. 27, p. 282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  187. I. A. Abdelgawad, N. H. Radwan, R. E. Shafik, and H. A. Shokralla, “Significance of some proliferation markers and some prognostic factors in patients with multiple myeloma and their impact on the patients’ survival,” Asian Pacific Journal of Cancer Prevention, vol. 17, pp. 2389–2394, 2016. View at Google Scholar
  188. A. Billiau, H. Heremans, K. Vermeire, and P. Matthys, “Immunomodulatory properties of interferon-gamma. An update,” Annals of the New York Academy of Sciences, vol. 856, pp. 22–32, 1998. View at Publisher · View at Google Scholar
  189. A. E. Hauser, G. F. Debes, S. Arce et al., “Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response,” Journal of Immunology, vol. 169, pp. 1277–1282, 2002. View at Publisher · View at Google Scholar
  190. C. Moller, T. Stromberg, M. Juremalm, K. Nilsson, and G. Nilsson, “Expression and function of chemokine receptors in human multiple myeloma,” Leukemia, vol. 17, pp. 203–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  191. K. Moser, G. Muehlinghaus, R. Manz et al., “Long-lived plasma cells in immunity and immunopathology,” Immunology Letters, vol. 103, pp. 83–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  192. N. Giuliani, S. Bonomini, P. Romagnani et al., “CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival,” Haematologica, vol. 91, pp. 1489–1497, 2006. View at Google Scholar
  193. L. Escoubet-Lozach, I. L. Lin, and K. Jensen-Pergakes, “Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism,” Cancer Research, vol. 69, pp. 7347–7356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  194. A. Lopez-Girona, D. Heintel, L. H. Zhang et al., “Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response,” British Journal of Haematology, vol. 154, pp. 325–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  195. S. P. Eisenberg, R. J. Evans, W. P. Arend et al., “Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist,” Nature, vol. 343, pp. 341–346, 1990. View at Publisher · View at Google Scholar
  196. S. Li, A. Strelow, E. J. Fontana, and H. Wesche, “IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, pp. 5567–5572, 2002. View at Publisher · View at Google Scholar · View at Scopus
  197. G. Yang, Y. Zhou, X. Liu et al., “A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of bruton tyrosine kinase in Waldenstrom macroglobulinemia,” Blood, vol. 122, pp. 1222–1232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  198. A. Jain, S. Kaczanowska, and E. Davila, “IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance,” Frontiers in Immunology, vol. 5, p. 553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  199. A. Saxena, S. Khosraviani, S. Noel, D. Mohan, T. Donner, and A. R. Hamad, “Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy,” Cytokine, vol. 74, pp. 27–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  200. K. Josephson, N. J. Logsdon, and M. R. Walter, “Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site,” Immunity, vol. 15, pp. 35–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  201. D. Finbloom and K. Winestock, “IL-10 induces the tyrosine phosphorylation of tyk2 and jak1 and the differential assembly of STAT1 and STAT3 complexes in human T cells and monocytes,” Journal of Immunology, vol. 155, pp. 1079–1090, 1995. View at Google Scholar
  202. M. Matsuda, F. Salazar, M. Petersson et al., “Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression,” The Journal of Experimental Medicine, vol. 180, pp. 2371–2376, 1994. View at Publisher · View at Google Scholar
  203. D. Miotto, N. Lo Cascio, M. Stendardo et al., “CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer,” Lung Cancer, vol. 69, pp. 355–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  204. M. V. Lopez, S. K. Adris, A. I. Bravo, Y. Chernajovsky, and O. L. Podhajcer, “IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis,” Journal of Immunology, vol. 175, pp. 5885–5894, 2005. View at Publisher · View at Google Scholar
  205. S. Mocellin, F. M. Marincola, and H. A. Young, “Interleukin-10 and the immune response against cancer: a counterpoint,” Journal of Leukocyte Biology, vol. 78, pp. 1043–1051, 2005. View at Publisher · View at Google Scholar · View at Scopus
  206. D. Benjamin, C. D. Park, and V. Sharma, “Human B cell interleukin 10,” Leukemia & Lymphoma, vol. 12, pp. 205–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  207. M. Gupta, J. Han, M. Stenson et al., “Elevated serum IL10 levels in diffuse large B cell lymphoma: a mechanism of aberrant JAK2 activation,” Blood, vol. 119, pp. 2844–2853, 2012. View at Publisher · View at Google Scholar · View at Scopus
  208. E. Kovacs, “Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?” Leukemia Research, vol. 34, pp. 912–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. C. Pappa, S. Miyakis, G. Tsirakis et al., “Serum levels of interleukin 15 and interleukin 10 and their correlation with proliferating cell nuclear antigen in multiple myeloma,” Cytokine, vol. 37, pp. 171–5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  210. H. Wang, L. Wang, P. Chi et al., “High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma,” British Journal of Cancer, vol. 114, no. 4, pp. 463–468, 2016. View at Publisher · View at Google Scholar · View at Scopus
  211. M. G. Alexandrakis, N. Goulidaki, C. A. Pappa et al., “Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma,” Pathology Oncology Research, vol. 21, no. 4, pp. 929–934, 2015. View at Publisher · View at Google Scholar · View at Scopus
  212. T. Kasamatsu, T. Saitoh, R. Ino et al., “Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib,” Hematological Oncology, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  213. Z. Y. Lu, X. G. Zhang, C. Rodriguez et al., “Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells,” Blood, vol. 85, pp. 2521–2527, 1995. View at Google Scholar
  214. Z. J. Gu, V. Costes, Z. Y. Lu et al., “Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop,” Blood, vol. 88, pp. 3972–3986, 1996. View at Google Scholar
  215. K. R. Muthu Raja, L. Kubiczkova, L. Rihova et al., “Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment,” PLoS One, vol. 7, no. 11, article e49446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  216. T. Otsuki, K. Yata, H. Sakaguchi et al., “Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells,” British Journal of Haematology, vol. 116, no. 4, pp. 787–795, 2002. View at Publisher · View at Google Scholar · View at Scopus
  217. T. Kishimoto, S. Akira, M. Narazaki, and T. Taga, “Interleukin-6 family of cytokines and gp130,” Blood, vol. 86, pp. 1243–1254, 1995. View at Google Scholar
  218. J. Bromberg, “Stat proteins and oncogenesis,” The Journal of Clinical Investigation, vol. 109, pp. 1139–1142, 2002. View at Publisher · View at Google Scholar
  219. C. Garbers, H. M. Hermanns, F. Schaper et al., “Plasticity and cross-talk of interleukin 6-type cytokines,” Cytokine & Growth Factor Reviews, vol. 23, pp. 85–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  220. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, pp. 798–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  221. U. Schwertschlag, W. Trepicchio, K. Dykstra, J. Keith, K. Turner, and A. Dorner, “Hematopoietic, immunomodulatory and epithelial effects of interleukin-11,” Leukemia, vol. 13, pp. 1307–1315, 1999. View at Publisher · View at Google Scholar
  222. M. Teramura, S. Kobayashi, K. Yoshinaga, K. Iwabe, and H. Mizoguchi, “Effect of interleukin 11 on normal and pathological thrombopoiesis,” Cancer Chemotherapy and Pharmacology, vol. 38, pp. S99–S102, 1996. View at Publisher · View at Google Scholar
  223. G. Huang, L. Yu, L. J. Cooper, M. Hollomon, H. Huls, and E. S. Kleinerman, “Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases,” Cancer Research, vol. 72, pp. 271–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  224. H. Urbańska-Ryś, A. Wiersbowska, H. Stepień, and T. Robak, “Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma,” European Cytokine Network, vol. 11, no. 3, pp. 443–451, 2000. View at Google Scholar
  225. N. Giuliani, S. Colla, F. Morandi, and V. Rizzoli, “The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment,” Haematologica, vol. 89, no. 9, pp. 1118–1123, 2004. View at Google Scholar
  226. N. Giuliani, M. Ferretti, M. Bolzoni et al., “Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation,” Leukemia, vol. 26, no. 6, pp. 1391–1401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  227. C. B. Childs, J. A. Proper, R. F. Tucker, and H. L. Moses, “Serum contains a platelet-derived transforming growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, pp. 5312–5316, 1982. View at Google Scholar
  228. J. L. Wrana, L. Attisano, R. Wieser, F. Ventura, and J. Massague, “Mechanism of activation of the TGF-beta receptor,” Nature, vol. 370, pp. 341–347, 1994. View at Publisher · View at Google Scholar
  229. A. Nakao, T. Imamura, S. Souchelnytskyi et al., “TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4,” The EMBO Journal, vol. 16, pp. 5353–5362, 1997. View at Publisher · View at Google Scholar · View at Scopus
  230. J. Massague and D. Wotton, “Transcriptional control by the TGF-beta/Smad signaling system,” The EMBO Journal, vol. 19, pp. 1745–1754, 2000. View at Publisher · View at Google Scholar
  231. L. Gorelik and R. A. Flavell, “Transforming growth factor-beta in T-cell biology,” Nature Reviews. Immunology, vol. 2, pp. 46–53, 2002. View at Publisher · View at Google Scholar
  232. J. J. Letterio and A. B. Roberts, “Regulation of immune responses by TGF-beta,” Annual Review of Immunology, vol. 16, pp. 137–161, 1998. View at Publisher · View at Google Scholar · View at Scopus
  233. J. H. Kehrl, A. B. Roberts, L. M. Wakefield, S. Jakowiew, M. B. Sporn, and A. S. Fauci, “Transforming growth factor Beta is an important immunomodulatory protein for human B lymphocytes,” Journal of Immunology, vol. 137, pp. 3855–3860, 1986. View at Google Scholar
  234. T. Hayashi, T. Hideshima, A. N. Nguyen et al., “Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment,” Clinical Cancer Research, vol. 10, no. 22, pp. 7540–7546, 2004. View at Publisher · View at Google Scholar · View at Scopus
  235. K. E. Lambert, H. Huang, K. Mythreye, and G. C. Blobe, “The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells,” Molecular Biology of the Cell, vol. 22, pp. 1463–1472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  236. I. Bruns, R.P. cadeddu, I. Brueckmann et al., “TGF-b inhibition restores terminal osteoblast differentiation to suppress myeloma growth,” PLoS One, vol. 5, article e9870, 2010. View at Publisher · View at Google Scholar · View at Scopus
  237. T. Matsumoto and M. Abe, “TGF-β-related mechanisms of bone destruction in multiple myeloma,” Bone, vol. 48, pp. 129–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  238. M. A. Frassanito, K. DeVeirman, V. Desantis et al., “Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients,” Leukemia, vol. 30, no. 3, pp. 640–648, 2016. View at Publisher · View at Google Scholar · View at Scopus
  239. M. Dong and G. C. Blobe, “Role of transforming growth factor-beta in hematologic malignancies,” Blood, vol. 107, pp. 4589–4596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  240. N. O. Temajo and N. Howard, “The virus-induced HSPs regulate the apoptosis of operates APCs that results in autoimmunity, not in homeostasis,” Autoimmunity Reviews, vol. 13, pp. 1013–1019, 2014. View at Publisher · View at Google Scholar · View at Scopus
  241. H. Udono, “Heat shock protein magic in antigen trafficking within dendritic cells: implications in antigen cross-presentation in immunity,” Acta Medica Okayama, vol. 66, pp. 1–6, 2012. View at Publisher · View at Google Scholar
  242. D. F. Terry, D. F. Wyszynski, V. G. Nolan et al., “Serum heat shock protein 70 level as a biomarker of exceptional longevity,” Mechanisms of Ageing and Development, vol. 127, pp. 862–868, 2006. View at Publisher · View at Google Scholar · View at Scopus
  243. S. A. Fuqua, S. Oesterreich, S. G. Hilsenbeck, D. D. Von Hoff, J. Eckardt, and C. K. Osborne, “Heat shock proteins and drug resistance,” Breast Cancer Research and Treatment, vol. 32, pp. 67–71, 1994. View at Google Scholar
  244. L. M. Vargas-Roig, F. E. Gago, O. Tello, J. C. Aznar, and D. R. Ciocca, “Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy,” International Journal of Cancer, vol. 79, pp. 468–475, 1998. View at Google Scholar
  245. J. S. Isaacs, W. Xu, and L. Neckers, “Heat shock protein 90 as a molecular target for cancer therapeutics,” Cancer Cell, vol. 3, pp. 213–217, 2003. View at Google Scholar
  246. A. Mahindra, D. Cirstea, and N. Raje, “Novel therapeutic targets for multiple myeloma,” Future Oncology, vol. 6, pp. 407–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  247. S. Takayama, J. C. Reed, and S. Homma, “Heat-shock proteins as regulators of apoptosis,” Oncogene, vol. 22, pp. 9041–9047, 2003. View at Publisher · View at Google Scholar · View at Scopus
  248. L. Whitesell and S. L. Lindquist, “HSP90 and the chaperoning of cancer,” Nature Reviews. Cancer, vol. 5, pp. 761–772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  249. T. Van den Berghe, M. Kalai, G. van Loo, W. Declercq, and P. Vandenabeele, “Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis,” The Journal of Biological Chemistry, vol. 278, pp. 5622–5629, 2003. View at Publisher · View at Google Scholar · View at Scopus
  250. G. Chen, P. Cao, and D. V. Goeddel, “TNF-induced recruitment and activation of the IkK complex require Cdc37 and HSP90,” Molecular Cell, vol. 9, pp. 401–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  251. F. M. Falsone, S. Leptihn, A. Osterauer, M. Haslbeck, and J. Buchner, “Oncogenic mutations reduce the stability of Src kinase,” Journal of Molecular Biology, vol. 344, pp. 281–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  252. L. Whitesell, P. D. Sutphin, E. J. Pulcini, J. D. Martinez, and P. H. Cook, “The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an HSP90-binding agent,” Molecular and Cellular Biology, vol. 18, pp. 1517–1524, 1998. View at Publisher · View at Google Scholar
  253. L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers, and L. M. Neckers, “Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, pp. 8324–8328, 1994. View at Publisher · View at Google Scholar
  254. A. Stephanou, D. A. Isenberg, S. Akira, T. Kishimoto, and D. S. Latchman, “The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the HSP90beta gene by interleukin-6 but have opposite effects on its inducibility by heat shock,” The Biochemical Journal, vol. 330, pp. 1189–1195, 1998. View at Publisher · View at Google Scholar
  255. D. V. Kalvakolanu and S. K. Roy, “CCAAT⁄enhancer binding proteins and interferon signaling pathways,” Journal of Interferon & Cytokine Research, vol. 25, pp. 757–769, 2005. View at Publisher · View at Google Scholar · View at Scopus
  256. M. Andrulis, M. Chatterjee, S. Jain et al., “Heat shock protein 90 alpha and beta are overexpressed in multiple myeloma cells and critically contribute to survival,” Verhandlungen der Deutschen Gesellschaft für Pathologie, vol. 91, pp. 330–337, 2009. View at Google Scholar
  257. A. Allegra, E. Sant’Antonio, G. Penna et al., “Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors,” European Journal of Haematology, vol. 86, no. 2, pp. 93–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  258. N. Mitsiades, C. S. Mitsiades, P. G. Richardson et al., “Molecular sequelae of histone deacetylase inhibition in human malignant B cells,” Blood, vol. 101, pp. 4055–4062, 2003. View at Publisher · View at Google Scholar · View at Scopus
  259. X. Y. Pei, Y. Dai, and S. Grant, “Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors,” Clinical Cancer Research, vol. 10, pp. 3839–3852, 2004. View at Publisher · View at Google Scholar · View at Scopus
  260. C. Y. Gui, L. Ngo, W. S. Xu, V. M. Richon, and P. A. Marks, “Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, pp. 1241–1246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  261. Y. Imai, Y. Maru, and J. Tanaka, “Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies,” Cancer Science, vol. 107, pp. 1543–1549, 2016. View at Publisher · View at Google Scholar · View at Scopus
  262. Y. Xie, O. Bai, H. Zhang et al., “Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70,” Journal of Cellular and Molecular Medicine, vol. 11, pp. 2655–2666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  263. S. H. Jung, Y. K. Lee, H. J. Lee et al., “Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro,” Experimental Hematology, vol. 42, pp. 274–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  264. S. C. Larsson and A. Wolk, “Body mass index and risk of multiple myeloma: a meta-analysis,” International Journal of Cancer, vol. 121, pp. 2512–2516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  265. M. Dalamaga, “Interplay of adipokines and myokines in cancer pathophysiology: emerging therapeutic implications,” World Journal of Experimental Medicine, vol. 3, no. 3, pp. 26–33, 2013. View at Publisher · View at Google Scholar
  266. I. Mahú and A. I. Domingos, “The sympathetic neuro-adipose connection and the control of body weight,” Experimental Cell Research, 2017. View at Publisher · View at Google Scholar
  267. A. Pérez-Pérez, T. Vilariño-García, P. Fernández-Riejos, J. Martín-González, J. J. Segura-Egea, and V. Sánchez-Margalet, “Role of leptin as a link between metabolism and the immune system,” Cytokine & Growth Factor Reviews, vol. 35, pp. 71–84, 2017. View at Publisher · View at Google Scholar
  268. F. Corica, A. Allegra, A. Corsonello et al., “Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects,” International Journal of Obesity and Related Metabolic Disorders, vol. 23, no. 4, pp. 355–360, 1999. View at Publisher · View at Google Scholar
  269. J. N. Hofmann, L. M. Liao, M. N. Pollak et al., “A prospective study of circulating adipokine levels and risk of multiple myeloma,” Blood, vol. 120, no. 22, pp. 4418–4420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  270. N. E. Esheba, A. Shahba, and O. El Shora, “Assessment of leptin and resistin levels in non-obese multiple myeloma patients and their relation with Ig level and disease stage,” Journal of the Egyptian National Cancer Institute, vol. 26, pp. 61–66, 2014. View at Publisher · View at Google Scholar · View at Scopus
  271. M. G. Alexandrakis, F. H. Passam, A. Sfiridaki et al., “Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines,” The International Journal of Biological Markers, vol. 19, pp. 52–57, 2004. View at Publisher · View at Google Scholar
  272. I. Ray, S. K. Mahata, and R. K. De, “Obesity: an immunometabolic perspective,” Frontiers in Endocrinology, vol. 7, p. 157, 2016. View at Publisher · View at Google Scholar · View at Scopus
  273. R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” The New England Journal of Medicine, vol. 334, pp. 292–295, 1996. View at Publisher · View at Google Scholar · View at Scopus
  274. P. Rider, Y. Carmi, and I. Cohen, “Biologics for targeting inflammatory cytokines, clinical uses, and limitations,” International Journal of Cell Biology, vol. 2016, Article ID 9259646, 11 pages, 2016. View at Publisher · View at Google Scholar
  275. H. Quach, D. Ritchie, A. K. Stewart et al., “Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma,” Leukemia, vol. 24, no. 1, pp. 22–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  276. V. Kotla, S. Goel, S. Nischal et al., “Mechanism of action of lenalidomide in hematological malignancies,” Journal of Hematology & Oncology, vol. 2, p. 36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  277. L. G. Corral, P. A. Haslett, G. W. Muller et al., “Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha,” Journal of Immunology, vol. 163, no. 1, pp. 380–386, 1999. View at Google Scholar
  278. T. Harada, S. Ozaki, A. Oda et al., “Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma,” International Journal of Hematology, vol. 97, pp. 743–748, 2013. View at Publisher · View at Google Scholar · View at Scopus
  279. S. Zha, V. Yegnasubramanian, W. G. Nelson, W. B. Isaacs, and A. M. De Marzo, “Cyclooxygenases in cancer: progress and perspective,” Cancer Letters, vol. 215, pp. 1–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  280. M. Ladetto, S. Vallet, A. Trojan et al., “Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome,” Blood, vol. 105, pp. 4784–4791, 2005. View at Publisher · View at Google Scholar · View at Scopus
  281. A. Trojan, M. Tinguely, S. Vallet et al., “Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma,” Swiss Medical Weekly, vol. 136, pp. 400–403, 2006. View at Publisher · View at Google Scholar
  282. M. Cetin, S. Buyukberber, M. Demir et al., “Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival,” American Journal of Hematology, vol. 80, pp. 169–173, 2005. View at Publisher · View at Google Scholar · View at Scopus
  283. M. Zhang, Y. Abe, T. Matsushima, J. Nishimura, H. Nawata, and K. Muta, “Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway,” Leukemia & Lymphoma, vol. 46, pp. 425–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  284. J. Ding, K. Tsuboi, H. Hoshikawa et al., “Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in anti-proliferative effect of cyclooxygenase inhibitors,” Molecular Carcinogenesis, vol. 45, pp. 250–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  285. R. Khan, M. Sharma, L. Kumar, S. Akhtar Husain, and A. Sharma, “Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma,” Annals of Hematology, vol. 92, pp. 101–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  286. P. L. Minciullo, A. Catalano, G. Mandraffino et al., “Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity,” Archivum Immunologiae et Therapiae Experimentalis, vol. 64, no. 2, pp. 111–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  287. D. Monti, R. Ostan, V. Borell, G. Castellani, and C. Franceschi, “Inflammaging and human longevity in the omics era,” Mechanisms of Ageing and Development, vol. 165, Part B, pp. 129–138, 2016. View at Publisher · View at Google Scholar
  288. K. Klintrup, J. M. Mäkinen, S. Kauppila et al., “Inflammation and prognosis in colorectal cancer,” European Journal of Cancer, vol. 41, no. 17, pp. 2645–2654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  289. A. H. Lee, C. E. Gillett, K. Ryder, I. S. Fentiman, D. W. Miles, and R. R. Millis, “Different patterns of inflammation and prognosis in invasive carcinoma of the breast,” Histopathology, vol. 48, no. 6, pp. 692–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  290. T. Cai, G. Nesi, V. Boddi, S. Mazzoli, M. Dal Canto, and R. Bartoletti, “Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma,” Oncology Reports, vol. 16, no. 2, pp. 329–334, 2006. View at Publisher · View at Google Scholar
  291. S. Z. Ben-Sasson, J. Hu-Li, J. Quiel et al., “IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7119–7124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  292. O. A. W. Haabeth, K. B. Lorvik, C. Hammarström et al., “Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer,” Nature Communications, vol. 2, p. 240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  293. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  294. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  295. W. W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” The Journal of Clinical Investigation, vol. 117, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  296. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  297. S. Kim, H. Takahashi, W. W. Lin et al., “Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis,” Nature, vol. 457, no. 7225, pp. 102–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  298. E. J. Park, J. H. Lee, G. Y. Yu et al., “Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression,” Cell, vol. 140, no. 2, pp. 197–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  299. R. Philip and L. B. Epstein, “Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1,” Nature, vol. 323, pp. 86–89, 1986. View at Publisher · View at Google Scholar
  300. F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  301. F. Ghiringhelli, L. Apetoh, A. Tesniere et al., “Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors,” Nature Medicine, vol. 15, no. 10, pp. 1170–1178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  302. A. Allegra, G. Penna, A. Alonci, V. Rizzo, S. Russo, and C. Musolino, “Nanoparticles in oncology: the new theragnostic molecules,” Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 7, pp. 669–686, 2011. View at Publisher · View at Google Scholar
  303. M. J. Mitchell, J. Webster, A. Chung, P. P. Guimarães, O. F. Khan, and R. Langer, “Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis,” Nature Communications, vol. 8, article 14179, 2017. View at Publisher · View at Google Scholar
  304. V. Shukla, M. Dalela, M. Vij et al., “Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system,” Nanomedicine, vol. 13, no. 5, pp. 1833–1839, 2017. View at Publisher · View at Google Scholar